article Open AccessTop 1% cited

Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy

Clinical Cancer Research · 2005 · Vol. 11(16) · pp. 5678–5685

Roman Rouzier✉(Institut Gustave Roussy)Charles M. Perou(UNC Lineberger Comprehensive Cancer Center)W. Fraser SymmansNuhad K. IbrahimMassimo CristofanilliK. Anderson(Applied Mathematics (United States))Kenneth R. Hess(Applied Mathematics (United States))James Stec(Albany Medical Center Hospital)Mark Ayers(Millennium Engineering and Integration (United States))Peter J. WagnerPaolo MorandiChang Fan(University of North Carolina at Chapel Hill)Rabiul IslamJeffrey S. Ross(Millennium Engineering and Integration (United States))Gabriel N. HortobágyiLajos Pusztai

View via DOI Full-text PDF

Abstract

The basal-like and erbB2+ subtypes of breast cancer are more sensitive to paclitaxel- and doxorubicin-containing preoperative chemotherapy than the luminal and normal-like cancers.

Breast Cancer Treatment Studies HER2/EGFR in Cancer Research Gene expression and cancer classificationBreast cancerChemotherapyOncologyCancerInternal medicinePaclitaxelDoxorubicinEstrogen receptorCyclophosphamideMedicine

MeSH terms

AdultAgedAntineoplastic Combined Chemotherapy ProtocolsBiopsy, NeedleBreastBreast NeoplasmsDoxorubicinFemaleFluorouracilHumansMiddle AgedPredictive Value of TestsPreoperative CareGene Expression Regulation, NeoplasticMultivariate Analysis

Citations

1,881

FWCI

37.27

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype